Winton Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Winton Group’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$207K	Buy	+28,403	New	+$268K	0.01%	941

Other funds holding PHAT

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Winton Group's PHAT Position: Q3 2026 in Review

Winton Group opened a new position in Phathom Pharmaceuticals (PHAT) in Q3 2026: 28,403 shares worth $207K. The stake represents 0.01% of the portfolio and ranks #941 among its holdings.

94 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

Winton Group held 28,403 shares of Phathom Pharmaceuticals worth $207K as of Q3 2026.
Phathom Pharmaceuticals was a new Winton Group position in Q3 2026.
Phathom Pharmaceuticals made up 0.01% of Winton Group's portfolio in Q3 2026, its #941 holding.
94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.